Effectiveness of SGLT2 inhibitors in slowing chronic kidney disease progression and reducing mortality: a meta-analysis

More on Chronic kidney disease

• Lower physical performance links to heart failure and death in CKD

  Clinical Journal of the American Society of Nephrology · 4 Oct 2026

• SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes

  Clinical Journal of the American Society of Nephrology · 4 Oct 2026

• SGLT2 inhibitors raise genital but not urinary infection risk

  Clinical Pharmacology and Therapeutics · 4 Oct 2026

• Underweight is linked to higher kidney disease risk in diabetes

  Frontiers in Endocrinology · 4 Oct 2026